NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately ...
NORTH CHICAGO, Ill., June 15, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from COMMAND, its Phase 3 maintenance study, showing risankizumab (SKYRIZI ®, 180 mg or ...
NORTH CHICAGO, Ill., Aug. 28, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and ...
Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising superstar Skyrizi. Despite the fall of what was once the world’s top-selling ...
Clinical Trials Arena on MSN
UCB’s Bimzelx bests Skyrizi in Phase III PsA study, but analysts sceptical
While this result affirms Bimzelx’s efficacy in PsA, analysts do not believe this readout will have a notable impact on the ...
In early March 2026, AbbVie reported positive topline Phase 3 AFFIRM data showing risankizumab (SKYRIZI) subcutaneous induction achieved significantly higher clinical remission and endoscopic response ...
In the Phase 3 AFFIRM study in adults with moderately to severely active Crohn's disease, risankizumab (SKYRIZI ®) achieved superiority for the co-primary and ranked secondary endpoints at week 12 for ...
Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results